Industry news
Valeant Pharmaceuticals acquires Sprout Pharmaceuticals for $1 billion
Valeant Pharmaceuticals will acquire Sprout Pharmaceuticals for $1 billion and with it the controversial Addyi (flibanserin), the recently FDA approved treatment for female sexual dysfunction. Valeant plans to build a women's health division around the drug.